Plasma and intracellular Mg2+ concentrations in pre-eclampsia

Area of Science:

• Obstetrics and Gynecology
• Clinical Biochemistry
• Cardiovascular Research

Background:

• Pre-eclampsia is a serious pregnancy complication characterized by hypertension.
• Magnesium (Mg2+) plays a crucial role in various physiological processes, including vascular tone regulation.
• Alterations in magnesium (Mg2+) status have been implicated in hypertensive disorders.

Purpose of the Study:

• To investigate plasma and intra-erythrocytic magnesium (Mg2+) concentrations in pre-eclamptic patients compared to healthy pregnant women.
• To assess the effect of magnesium (Mg2+) salt treatment on intra-erythrocytic magnesium (Mg2+) levels in pre-eclampsia.

Main Methods:

• Comparative analysis of plasma and red blood cell magnesium (Mg2+) levels.
• Measurement of magnesium (Mg2+) concentrations in 27 pre-eclamptic patients and 22 healthy pregnant women.
• Monitoring magnesium (Mg2+) levels before and after magnesium (Mg2+) salt treatment and postpartum.

Main Results:

• No significant difference in plasma magnesium (Mg2+) concentrations between groups.
• Significantly lower intra-erythrocytic magnesium (Mg2+) in pre-eclamptic patients before treatment (1.01 +/- 0.16 mmol/l) versus healthy controls (1.33 +/- 0.29 mmol/l).
• Intra-erythrocytic magnesium (Mg2+) levels increased after magnesium (Mg2+) treatment in pre-eclamptic patients (1.19 +/- 0.24 mmol/l).

Conclusions:

• Reduced intracellular magnesium (Mg2+) may be a contributing factor to hypertension in pre-eclampsia.
• Magnesium (Mg2+) supplementation shows potential in normalizing cellular magnesium (Mg2+) levels.
• Further research is warranted to explore magnesium's (Mg2+) therapeutic role in pre-eclampsia management.